Biocon's Q1 FY 2026-27 Quarterly Results

Result Summary

• Biocon Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 9.2%.
• Its expenses for the quarter were up by 0.2% QoQ and 8.3% YoY.
• The net profit decreased 31.1% QoQ and increased 53.4% YoY.
• The earnings per share (EPS) of Biocon Ltd stood at 0.87 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Biocon Ltd is a prominent biopharmaceutical company based in India. The company primarily focuses on the development, manufacturing, and commercialization of biopharmaceutical products. Biocon operates in the healthcare sector, offering a wide range of products and services including generic active pharmaceutical ingredients (APIs), biosimilars, and research services. The company is known for its work in the production of insulin, monoclonal antibodies, and other complex biologics. Biocon has been at the forefront of innovation in the biopharmaceutical industry, with a strong emphasis on improving access to high-quality, affordable healthcare solutions. Regarding recent major developments, specific information isn't provided in the data, but Biocon is typically involved in strategic collaborations, product launches, and expansion of its market footprint.

Revenue

Biocon Ltd reported a total income of ₹4390.50 crores in Q1FY27, reflecting a decrease when compared to the previous quarter, Q4FY26, which stood at ₹4569.10 crores. This denotes a quarter-over-quarter (QoQ) decline of 3.9%. However, when compared to the same quarter in the previous year, Q1FY26, the total income showed a year-over-year (YoY) growth of 9.2%, having increased from ₹4021.60 crores. The financial data indicates that while there was a decline in total income on a sequential quarterly basis, there was an upward trend when viewed on an annual basis, suggesting a stronger revenue performance compared to the previous year.

Profitability

In terms of profitability, Biocon Ltd's profit before tax for Q1FY27 was reported at ₹127.60 crores. This figure represents a significant decline of 48.4% from the previous quarter, Q4FY26, where the profit before tax was ₹247.50 crores. Despite this quarterly decline, there was a notable year-over-year increase of 31.7% from Q1FY26, where the profit before tax stood at ₹96.90 crores. The tax expense for Q1FY27 was a negative ₹9.20 crores, compared to a tax expense of ₹48.90 crores in Q4FY26, and ₹7.70 crores in Q1FY26, reflecting significant fluctuations. The profit after tax for Q1FY27 amounted to ₹136.80 crores, a decrease of 31.1% from Q4FY26's ₹198.60 crores, yet a substantial increase of 53.4% from ₹89.20 crores in Q1FY26. Earnings per share (EPS) for Q1FY27 was ₹0.87, indicating a QoQ increase of 10.1% from ₹0.79 in Q4FY26, and a substantial YoY increase of 234.6% from ₹0.26 in Q1FY26.

Operating Metrics

Biocon Ltd's total expenses in Q1FY27 were ₹4249.40 crores, slightly higher by 0.2% compared to the previous quarter, Q4FY26, where the expenses were ₹4241.20 crores. When compared to Q1FY26, the total expenses increased by 8.3% from ₹3924.70 crores. This indicates that while expenses have been relatively stable on a quarterly basis, there has been an upward trend on an annual basis. The operating metrics, including the cost structure, reflect the company's resource allocation and operational efficiency over the reported periods. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not directly calculable from the provided data, as additional information like market capitalization, total debt, and current assets/liabilities is required. However, the provided earnings per share can be utilized in conjunction with stock prices to determine the P/E ratio if the market price is known. The data highlights the financial dynamics of Biocon's operations, emphasizing changes in income, expenses, and profitability metrics over the specified periods.